Johannes Popow - European Molecular Biology Laboratory

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 33 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyová,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumüller

crossref（2025）

Cited0Views0Bibtex

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyova,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumueller

CANCER DISCOVERYno. 1 (2025): 119-138

Cited0Views0WOSBibtex

Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification

Antonio Tedeschi,Fiorella Schischlik,Francesca Rocchetti,Johannes Popow, Florian Ebner,Daniel Gerlach, Antonia Geyer,Valeria Santoro,Andrew S Boghossian,Matthew G Rees,Melissa M Ronan,Jennifer A Roth,Jesse Lipp,Matthias Samwer,Michael Gmachl,Norbert Kraut,Mark Pearson,Dorothea Rudolph

Molecular cancer therapeuticsno. 4 (2025): 550-562

Cited0Views0WOSBibtex

100 (PB088): KRASmulti Inhibitor BI 3706674 Shows Efficacy in KRAS-driven Preclinical Models of Cancer That Supports Clinical Testing in Patients with Tumors Harboring KRASG12V Mutations and KRAS Wild-Type Amplifications

A. Tedeschi,D.H. Peng,F. Schischlik-Siegl,O. Schaaf,D. Gerlach,F. Rocchetti, J. Popow,J. Broeker,T. Wunberg,A.S. Boghossian,M.G. Rees,M.M. Ronan,J.A. Roth, M. Williams,C. Vellano,J.R. Marszalek,T.P. Heffernan,M. Pearson,N. Kraut,R. Dorothea

European Journal of Cancer (2024): 114624

Cited0Views0Bibtex

Targeting Cancer with Small-Molecule Pan-Kras Degraders

Johannes Popow,William Farnaby,Andreas Gollner,Christiane Kofink,Gerhard Fischer,Melanie Wurm,David Zollman,Andre Wijaya,Nikolai Mischerikow, Carina Hasenoehrl,Polina Prokofeva,Heribert Arnhof, Silvia Arce-Solano, Sammy Bell, Georg Boeck,Emelyne Diers, Aileen B. Frost, Jake Goodwin-Tindall,Jale Karolyi-Oezguer, Shakil Khan, Theresa Klawatsch,Manfred Koegl,Roland Kousek, Barbara Kratochvil, Katrin Kropatsch, Arnel A. Lauber,Ross Mclennan,Sabine Olt, Daniel Peter,Oliver Petermann, Vanessa Roessler,Peggy Stolt-Bergner,Patrick Strack,Eva Strauss,Nicole Trainor,Vesna Vetma,Claire Whitworth, Siying Zhong,Jens Quant,Harald Weinstabl,Bernhard Kuster,Peter Ettmayer,Alessio Ciulli

SCIENCEno. 6715 (2024): 1338-1347

Cited8Views0WOSBibtex

KRASmulti Inhibitor BI 3706674, an Orally Bioavailable, Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in KRASG12V-driven Preclinical Models

Cancer Researchno. 6_Supplement (2024): 3321-3321

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn